Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	740
Overall Study	STARTED	Lanabecestat 20 Milligrams (mg)	739
Overall Study	STARTED	Lanabecestat 50 mg	739
Overall Study	Received at Least 1 Dose of Study Drug	Placebo	738
Overall Study	Received at Least 1 Dose of Study Drug	Lanabecestat 20 Milligrams (mg)	736
Overall Study	Received at Least 1 Dose of Study Drug	Lanabecestat 50 mg	735
Overall Study	COMPLETED	Placebo	187
Overall Study	COMPLETED	Lanabecestat 20 Milligrams (mg)	184
Overall Study	COMPLETED	Lanabecestat 50 mg	168
Overall Study	NOT COMPLETED	Placebo	553
Overall Study	NOT COMPLETED	Lanabecestat 20 Milligrams (mg)	555
Overall Study	NOT COMPLETED	Lanabecestat 50 mg	571

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02245737/flow